Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I diabetic mice

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 1, 2007, Pages

  Nasrallah, Rania ^a   Xiong, Huaqi ^a   Hébert, Richard L ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cyclooxygenase; Real time reverse transcriptase polymerase chain reaction; Renal EP receptors; Streptozotocin diabetic mice

Indexed keywords

ALBUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLUCOSE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E3; STREPTOZOCIN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY MASS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; IMMUNOENZYME TECHNIQUES; KIDNEY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 33846221133     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00089.2006     Document Type: Article

References (46)

1. Bakris Gl, Starke U, Heifets M, Polack D, Smith M, Leurgans S. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol 5: 1684-1688, 1995.
2. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron 87: 8-18, 2001.
3. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner TW, Bronson SK. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 46: 2210-2218, 2005.
4. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 42, Suppl 1: S42-S49, 2005.
5. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res 512: 121-134, 2002.
6. Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol Renal Fluid Electrolyte Physiol 253: F377-F387, 1987.
7. Breyer MD, Bottinger E, Brosius FC III, Coffman TM, Harris RC, Heilig CW, Sharma K, AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
8. Breyer M, Breyer R. Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 279: F12-F23, 2000.
9. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 36: 449-467, 2000.
10. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
11. Craven PA, Caines MA, DeRubertis FR. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 36: 95-103, 1987.
12. Craven PA, Melhem MF, DeRubertis FR. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 42: 937-946, 1992.
13. DeRubertis FR, Craven PA. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 22: 727-735, 1993.
14. 2. Am J Physiol Renal Physiol 275: F955-F961, 1998.
15. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290: F214-F222, 2006.
16. Haseyama T, Fujita T, Hirasawa F, Tsukada M. Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse. Tohoku J Exp Med 198: 233-244, 2002.
17. Hébert RL, Breyer RM, Jacobson HR, Breyer MD. Functional and molecular aspects of prostaglandin E receptors in the cortical collecting duct. Can J Physiol Pharmacol 73: 172-179, 1995.
18. 2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 265: F643-F650, 1993.
19. 2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol Renal Fluid Electrolyte Physiol 259: F318-F325, 1990.
20. Ishibashi R, Tanaka I, Kotani M, Muro S, Goto M, Sugawara A, Mukoyama M, Sugimoto Y, Ichikawa A, Narumiya S, Nakao K. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 56: 589-600, 1999.
21. 4 receptors in the rat kidney. Am J Physiol Renal Physiol 280: F1001-F1009, 2001.
22. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101: 13302-13305, 2004.
23. 2 receptor. Nat Med 5: 217-220, 1999.
24. Knepper MA, Wade JB, Terris J, Ecelbarger CA, Marples D, Mandon B, Chou C, Kishore BK, Nielsen S. Renal aquaporins. Kidney Int 49: 1712-1717, 1996.
25. Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, Yasuda O, Fukuo K, Ogihara T. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 20: 242-252, 1999.
26. Komers R, Zdychova J, Cahova M, Kazdova L, Lindsley JN, Anderson S. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67: 2151-2158, 2005.
27. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107: 889-898, 2001.
28. Leung JCK, Chan LYY, Tsang AWL, Tang SCW, Lai KN. Differential expression of aquaporins in the kidneys of streptozotocin-induced diabetic mice. Nephrology 10: 63-72, 2005.
29. 1-selective antagonist. J Am Soc Nephrol 13: 1757-1765, 2002.
30. 4 receptor expression in podocytes: implications for the actin cytoskeleton. Am J Physiol Renal Physiol 286: F693-F701, 2004.
31. Mathiesen ER, Hommel E, Olsen UB, Parving HH. Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy. Diabet Med 5: 145-149, 1988.
32. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 79: 1193-1226, 1999.
33. Nasrallah R, Hébert RL. Reduced IP receptors in STZ-induced diabetic rat kidneys and high-glucose-treated mesangial cells. Am J Physiol Renal Physiol 287: F673-F681, 2004.
34. 2/IP system in cultured rat mesangial cells. Prostaglandins Leukot Essent Fatty Acids 70: 455-464, 2004.
35. Nasrallah R, Landry A, Singh S, Sklepowicz M, Hébert RL. Increased expression of cyclooxygenase-1 and -2 in the diabetic rat renal medulla. Am J Physiol Renal Physiol 285: F1068-F1077, 2003.
36. 4 triggers remodelling of the cardiovascular system at birth. Nature 390: 78-81, 1997.
37. 2 in incipient diabetic nephropathy. Nephron 92: 788-796, 2002.
38. Robles RG, Villa E, Rabano A, Alvarez E, Martinez J, Ruilope LM, Sancho JM. Effect of cicaprost on the progression of diabetic nephropathy in uninephrectomized streptozotocin-induced diabetic rats. J Hypertens 11, Suppl 5: S208-S209, 1993.
39. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effect of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66: 76-84, 1999.
40. Schlein PS, O'Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, Wiernik PH, Ziegler JL, DeVita VT. Clinical antitumor activity and toxicity of streptozotocin. Cancer 34: 993-1000, 1974.
41. 1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107: 325-331, 2001.
42. Sugimoto Y, Namba T, Shigemoto R, Negishi M, Ichikawa A, Narumiya S. Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. Am J Physiol Renal Fluid Electrolyte Physiol 266: F823-F828, 1994.
43. Tajiri Y, Umeda F, Inoguchi T, Nawata H. Effects of thromboxane synthase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. J Diabetes Complications 8: 126-132, 1994.
44. 2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci 116: 3285-3294, 2003.
45. Waldner C, Heise G, Schror K, Heering P. COX-2 inhibition and prostaglandin receptors in experimental nephritis. Eur J Clin Invest 33: 969-975, 2003.
46. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15, Suppl 1: S55-S57, 2004.